Ellevest Inc. Sells 38,549 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Ellevest Inc. lowered its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 48.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 40,379 shares of the company's stock after selling 38,549 shares during the period. Ellevest Inc.'s holdings in Takeda Pharmaceutical were worth $535,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. QRG Capital Management Inc. grew its holdings in shares of Takeda Pharmaceutical by 16.8% during the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after purchasing an additional 47,490 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Takeda Pharmaceutical by 48.6% in the 4th quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock worth $600,000 after acquiring an additional 14,831 shares during the last quarter. US Bancorp DE grew its holdings in Takeda Pharmaceutical by 21.2% in the 4th quarter. US Bancorp DE now owns 124,332 shares of the company's stock worth $1,646,000 after acquiring an additional 21,744 shares during the last quarter. Blue Trust Inc. grew its holdings in Takeda Pharmaceutical by 27.0% in the 4th quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after acquiring an additional 3,071 shares during the last quarter. Finally, Park Avenue Securities LLC grew its holdings in Takeda Pharmaceutical by 28.3% in the 4th quarter. Park Avenue Securities LLC now owns 27,651 shares of the company's stock worth $366,000 after acquiring an additional 6,094 shares during the last quarter. Institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Down 1.4%

Takeda Pharmaceutical stock traded down $0.20 during trading hours on Monday, reaching $14.17. The stock had a trading volume of 5,381,637 shares, compared to its average volume of 1,903,078. The stock has a market cap of $45.07 billion, a PE ratio of 35.41, a PEG ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The company has a fifty day simple moving average of $14.86 and a 200-day simple moving average of $14.00.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.